Lipoprotein(a) and kidney diseases

Lipoprotein(a) [Lp(a)] is a subclass of lipoproteins consisting of a cholesterol-rich low-density lipoprotein (LDL) particle with a single apolipoprotein B100 molecule covalently bound (via a disulfide bridge) to a unique hydrophilic high-glycosylated protein called apolipoprotein a [apo(a)]. To date, there is sufficient evidence to consider an increase Lp(a) level as a causal and independent risk factor for cardiovascular disease and calcifying aortic valve stenosis. Plasma concentration of Lp(a) can vary in a wide range, which is mainly determined by genetic factors. Up to 30 % of the world's population has an elevated Lp(a) level, but this category of lipid disorders has not been currently receiving adequate attention. Determining the Lp(a) plasma concentrations is not included in the standard lipid profile, so a significant number of individuals with hyperlipoproteinemia(a) who could potentially benefit from treatment remain undiagnosed. Certain significant obstacles are still associated with the lack of standardized assay for measuring Lp(a) concentrations and a consensus on its optimal levels in blood plasma. Although some limited but statistically significant data suggest a possible benefit of lipoprotein(a) lowering on cardiovascular outcomes, no specific recommendations were made for the management of that dyslipidemia in the latest guidelines. Plasma Lp(a) levels reflect a balance of Lp(a) synthesis, which occurs in the liver, and catabolism, which is thought to involve the kidney. Lp(a) concentration begins already to increase in the earliest stages of chronic kidney disease, and patients with nephrotic syndrome have a four-fold elevated Lp(a) in comparison to healthy individuals. However, it remains unclear if elevated Lp(a) levels affect cardiovascular risk in patients with kidney diseases. This article summarizes the main data regarding the relationship between Lp(a) content, impaired renal function, and an increased risk of adverse cardiovascular events.

1. Benjamin E, Blaha M, Chiuve S et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485

2. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol 2017;69(6):692-711. doi: 10.1016/j.jacc.2016.11.042

3. Kukharchuk V, Yezhov M, Sergienko I et al. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis Russian recommendations, VII revision. Atherosclerosis and Dyslipidemias 2020; 1 (38): 7-40. doi: 10.34687/2219-8202.JAD.2020.01.0002

4. Mach F, Baigent C, Catapano A et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):111-188. doi: 10.1093/eurheartj/ehz455

5. Zychlinski A, Kleffmann T, Williams M et al. Proteomics of lipoprotein (a) identifies a protein complement associated with response to wounding. Journal of Proteomics 2011;74(12):2881-2891. doi: 10.1016/j.jprot.2011.07.008

6. Ward N, Kostner K, Sullivan D et al. Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far? J Clin Med 2019;8(12):2073. doi: 10.3390/jcm8122073

7. McCormick S, Schneider W. Lipoprotein(a) catabolism: a case of multiple receptors. Pathology 2019;51(2):155-164. doi: 10.1016/j.pathol.2018.11.003

8. Sharma М, Redpath G, Williams M et al. Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a). CircRes2017;120(7):1091е-1102е. doi: 10.1161/CIRCRESAHA.116.310272

9. Kronenberg F, Trenkwalder E, Lingenhel A et al. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res 1997;38:1755-1763

10. Reblin T, Donarski N, Fineder L et al. Renal handling of human apolipoprotein(a) and its fragments in the rat. Am J Kidney Dis 2001;38:619-630. doi: 10.1053/ajkd.2001.26889

11. Kostner K, Maurer G, Huber K et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996;16:905-911. doi: 10.1161/01.atv.16.8.905

12. Kronenberg F, Neyer U, Lhotta K et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 1999;10:1027-1036

13. Maranhao R, Carvalho P, Strunz et al. Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol 2014;103(1):76-84. doi: 10.5935/abc.20140101

14. Schmidt K, Noureen A, Kronenberg F et al. Structure, function, and genetics of lipoprotein (a). J Lipid Res 2016;57(8):1339-1359. doi: 10.1194/jlr.R067314

15. Suk Danik J, Rifai N, Buring J et al. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006;296:1363-1370. doi: 10.1001/jama.296.11.1363

16. Erqou S, Kaptoge S, Perry P et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-423. doi: 10.1001/jama.2009.1063

17. Kamstrup P, Benn M, Tybjaerg-Hansen A et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study. Circulation 2008;117:176-184. doi: 10.1161/CIRCULATIONAHA.107.715698

18. Verbeek R, Hoogeveen R, Langsted A et al. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J 2018;39(27):2589-2596. doi: 10.1093/eurheartj/ehy334

19. Rallidis L, Pavlakis G, Foscolou A et al. High levels of lipoprotein (a) and premature acute coronary syndrome. Atherosclerosis 2018;269:29-34. doi: 10.1016/j.atherosclerosis.2017.12.011

20. Steffen B, Duprez D, Bertoni A et al. Lp(a) [Lipoprotein(a)]-Related Risk of Heart Failure Is Evident in Whites but Not in Other Racial/Ethnic Groups. Arterioscler Thromb Vasc Biol 2018;38(10):2498-2504. doi: 10.1161/ATVBAHA.118.311220

21. Waldeyer C, Makarova N, Zeller T et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J 2017;38(32):2490-2498. doi: 10.1093/eurheartj/ehx166

22. O'Donoghue M, Fazio S, Giugliano R et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation 2019; 139(12):1483-1492. doi: 10.1161/CIRCULATIONAHA.118.037184

23. Ray K, Vallejo-Vaz A, Ginsberg H et al. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis 2019;88:194-202. doi: 10.1016/j.atheroscle-rosis.2019.06.896

24. Berg K, Dahlen G, Christophersen B et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997;52(5):254-261. doi: 10.1111/j.1399-0004.1997.tb04342.x

25. Hippe D, Phan B, Sun J et al. Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report. Arterioscler Thromb Vasc. Biol 2018;38(3):673-678. doi: 10.1161/ATVBAHA.117.310368

26. Lamina С, Kronenberg F. Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. JAMA Cardiol 2019;4(6):575-579. doi: 10.1001/jamacardio.2019.1041

27. Tsimikas S. Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis. Circ Res 2019;124:405-415. doi: 10.1161/CIRCRESAHA.118.313864

28. Muramatsu Y, Minami Y, Kato A et al. Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: An optical coherence tomography study. Int J Cardiol Heart Vasc 2019;24:100382. doi: 10.1161/CIRCRE-SAHA.118.313864

29. Loscalzo J, Weinfeld M, Fless G et al. Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990;10(2):240-245. doi: 10.1161/01.atv.10.2.240

30. Boffa M, Koschinsky M. Lipoprotein (a): Truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res 2016;57:745-757. doi: 10.1194/jlr.R060582

31. Kamstrup P, Tybjaerg-Hansen A, Nordestgaard B. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014;63:470-477. doi: 10.1016/j.jacc.2013.09.038

32. Capoulade R, Chan K, Yeang C et al. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. J Am Coll Cardiol 2015;66:1236-1246. doi: 10.1016/j.jacc.2015.07.020

33. Boden-Albala B, Kargman D, Lin I et al. Increased stroke risk and lipoprotein(a) in a multiethnic community: the Northern Manhattan Stroke Study. Cerebrovasc Dis 2010;30(3):237-243. doi: 10.1159/000319065

34. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 2007;38(6):1959-1966. doi: 10.1161/STROKEAHA.106.480657

35. Gurdasani D, Sjouke B, Tsimikas S et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterio-scler Thromb Vasc Biol 2012;32(12):3058-3065. doi: 10.1161/ATVBAHA.112.255521

36. Varvel S, McConnell J, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532359 patients in the United States. Arterioscler Thromb Vasc. Biol 2016;36(11):2239-2245. doi: 10.1161/ATVBAHA.116.308011

37. van Buuren F, Horstkotte D, Knabbe C et al. Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease. Clin Res Cardiol Suppl 2017;12(1):55-59. doi: 10.1007/s11789-017-0087-y

38. Jayasinghe R, Craig I, Mohan R. Lipoprotein (a) in clinical practice. J Pak Med Assoc 2014;64(4):447-450.

39. Najam O, Ray K. Lp(a) and cardiovascular disease-Has the phoenix finally risen from the ashes? Eur Heart J 2019;40:2771-2774. doi: 10.1093/eurheartj/ehz016

40. Tsimikas S, Fazio S, Ferdinand K et al. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol 2018;71:177-192. doi: 10.1016/j.jacc.2017.11.014

41. Grundy S, Stone N, Bailey A et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625

42. Saran R, Robinson B, Abbott K et al. US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 2017;69(3):A7-A8. doi: 10.1053/j. ajkd.2016.12.004

43. Kovesdy C, Astor B, Longenecker J et al. Association of kidney function with serum lipoprotein(a) level: the third National Health and Nutrition Examination Survey (1991- 1994). Am JKid-ney Dis 2002;40:899-908. doi: 10.1053/ajkd.2002.36319

44. Lin J, Reilly M, Terembula K et al. Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLoS One 2014;9:e114397. doi: 10.1371/journal.pone.0114397

45. Kronenberg F, Kuen E, Ritz E et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000;11:105-115.

46. Uhlig K, Wang S, Beck G et al. Factors associated with lipoprotein(a) in chronic kidney disease. Am J Kidney Dis 2005;45: 28-38. doi: 10.1053/j.ajkd.2004.08.043

47. Doucet B, Kostner K, Kaiser O et al. Live donor study -implications of kidney donation on cardiovascular risk with a focus on lipid parameters including lipoprotein a. Nephrology (Carlton) 2016;21:901-904. doi: 10.1111/nep.12792

48. Kronenberg F, Kathrein H, Konig P et al. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 1994;14:1405-1411. doi: 10.1161/01.atv.14.9.1405

49. Koch M, Kutkuhn B, Trenkwalder E et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997;8:1889-1898

50. Kronenberg F, Utermann G. Lipoprotein(a) - resurrected by genetics. J Intern Med 2013;273:6-30. doi: 10.1111/j.1365-2796.2012.02592.x

51. Gambhir J, Kalra O, Khaira A et al. Association between high molecular weight apolipoprotein isoforms and lipoprotein levels in advanced chronic kidney disease and the effect of hemodialysis. Indian J Nephrol 2013;23:18-23. doi: 10.4103/09714065.107189

52. Parsons D, Reaveley D, Pavitt D et al. Lipoprotein (a) levels in those with high molecular weight apo (a) isoforms may remain low in a significant proportion of patients with end-stage renal disease. Nephrol Dial Transplant 2003;18:1848-1853. doi: 10.1093/ndt/gfg276

53. Gault M, Longerich L, Purchase L et al. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron 1995;70:155-170. doi: 10.1159/000188578

54. Dieplinger H, Lackner C, Kronenberg F et al. Elevated plasma concentrations of lipoprotein(a) in patients with endstage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993;91:397-401. doi: 10.1172/JCI116213

55. Kronenberg F, Konig P, Neyer U et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995;6:110-120.

56. Kalra O, Khaira A, Gambhir J et al. Lipoprotein (a) in chronic renal failure: effect of maintenance hemodialysis. Hemodial Int 2003;7(4):326-331. doi: 10.1046/j.1492-7535.2003.00057.x

57. Barbagallo C, Averna M, Sparacino V et al. Lipoprotein (a) levels in end-stage renal failure and renal transplantation. Nephron 1993;64(4):560-564. doi: 10.1159/000187400

58. Irish A, Simons L, Savdie E et al. Lipoprotein (a) levels in chronic renal disease states, dialysis and transplantation. Aust NZ Med 1992;22(3):243-248. doi: 10.1111/j.1445-5994.1992.tb02119.x

59. Yun J, Ahn Y, Song K et al. Lipoprotein(a) predicts a new onset of chronic kidney disease in people with type 2 diabetes mellitus. Diabet Med 2016;33:639-643. doi: 10.1111/dme.12862

60. Emdin C, Khera A, Natarajan P et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. J Am Coll Cardiol 2016;68:2761-2772. doi: 10.1016/j.jacc.2016.10.033

61. Rahman M, Yang W, Akkina S et al. Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study. Clin J Am Soc Nephrol 2014;9:1190-1198. doi: 10.2215/CJN.09320913

62. Kronenberg F. Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol 2014;18:234-237. doi: 10.1007/s10157-013-0875-8

63. Vaziri N. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int 2016;90:41-52. doi: 10.1016/j.kint.2016.02.026

64. Stenvinkel P, Berglund L, Heimburger O et al. Lipoprotein(a) in nephrotic syndrome. Kidney Int 1993;44:1116-1123

65. Hong S, Yang D. Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome. Nephron 1995;69:125-130

66. Joven J, Simo J, Vilella E et al. Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria. Clin Chem 1995;41:908-913

67. Gansevoort R, Heeg J, Dikkeschei F et al. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 1994;9:244-250

68. Noto D, Barbagallo C, Cascio A et al. Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome. Kidney Int 1999;55:2433-2439. doi: 10.1046/j.1523-1755.1999.00489.x

69. De Sain-Van Der Velden M, Reijngoud D, Kaysen G et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 1998;9:1474-1481

70. Doucet C, Mooser V, Gonbert S et al. Lipoprotein(a) in the nephrotic syndrome: molecular analysis of lipoprotein(a) and apolipoprotein(a) fragments in plasma and urine. J Am Soc Nephrol 2000;11:507-513

71. Appel G, Blum C, Chien S et al. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 1985;312:1544-1548

72. Rosas S, Joffe M, Wolfe M et al. Effects of renal replacement therapy on plasma lipoprotein(a) levels. Am J Nephrol 2008;28:361-365. doi: 10.1159/000112225

73. Brown J, Anwar N, Short C et al. Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant 1993;8:863-867

74. Kostner K, Oberbauer R, Hoffmann U et al. Urinary excretion of apo(a) in patients after kidney transplantation. Nephrol Dial Transplant 1997;12:2673-2678

75. Hilbrands L, Demacker P, Hoitsma A et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995;5: 2073-2081

76. Brown J, Murphy B, Douglas A et al. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron 1997;75:277-282

77. Cauza E, Kletzmaier J, Bodlaj G et al. Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function. Nephrol Dial Transplant 2003;18:1568-1572. doi: 10.1093/ndt/gfg181

78. Kostner K, Jansen M, Maurer G et al. LDL-apheresis significantly reduces urinary apo (a) excretion. European Journal of Clinical Investigation 1997;27(1):93-95

79. Frank S, Hrzenjak A, Blaschitz A et al. Role of various tissues in apo(a) fragmentation and excretion of fragments by the kidney. Eur J Clin Invest 2001;31:504-512

80. Frischmann M, Kronenberg F, Trenkwalder E et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007;71(10):1036-1043. doi: 10.1038/sj.ki.5002131

81. Longenecker J, Klag M, Marcovina S et al. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study. Circulation 2002;106:2812-2818. doi: 10.1161/01.cir.0000038946.91899.bb

82. Longenecker J, Klag M, Marcovina S et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005;16:1794-1802. doi: 10.1681/ASN.2004110922

83. Shlipak M, Fried L, Cushman M et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005;293:1737-1745. doi: 10.1001/jama.293.14.1737

84. Bajaj A, Damrauer S, Anderson A et al. Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC study (Chronic Renal Insufficiency Cohort). Arterioscler Thromb Vasc Biol 2017;37:1971-1978. doi: 10.1161/ATVBAHA.117.309920

85. Vlad C, Burlacu A, Florea L et al. A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives. International Urology and Nephrology 2019;51(7):1173-1189. doi: 10.1007/s11255-019-02170-w

86. Kollerits B, Drechsler C, Krane V et al. Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study. Nephrol Dial Transplant 2016;31:1901-1908. doi: 10.1093/ndt/gfv428

87. Konishi H, Miyauchi K, Tsuboi S et al. Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention. Int J Cardiol 2016;205:50-53. doi: 10.1016/j.ijcard.2015.12.007

88. Pedersen T, McCormick S, Tsimikas S et al. Lipoprotein(a) accelerates atherosclerosis in uremic mice. J Lipid Res 2010;51(10):2967-2975. doi: 10.1194/jlr.M006742

89. Ma K, Gong T, Hu Z et al. Lipoprotein(a) accelerated the progression of atherosclerosis in patients with end-stage renal disease. BMC Nephrol 2018;19(1):192. doi: 10.1186/s12882-018-0986-2

90. Nave A, Lange K, Leonards C et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis 2015;242:496-503. doi: 10.1016/j.atherosclerosis.2015.08.021

91. Erqou S, Kaptoge S, Perry P et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-423. doi: 10.1001/jama.2009.1063

92. Chen Y, Zhan X, Zhao Q et al. Serum lipoprotein(a) and risk of hemorrhagic stroke among incident peritoneal dialysis patients: a large study from a single center in China. Renal Failure 2019;41(1):800-807. doi: 10.1080/0886022X.2019.1659151

93. Tonelli M, Wanner C. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med 2014;160(3):182. doi: 10.7326/M13-2453

94. Herrington W, Emberson J, Mihaylova B et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016;4(10):829-839. doi: 10.1016/S2213-8587(16)30156-5

95. Landray M, Haynes R, Hopewell J et al. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with la-ropiprant in high-risk patients. N Engl J Med 2014;371:203-212. doi: 10.1056/NEJMoa1300955

96. Anderson T, Boden W, Desvigne-Nickens P et al. AIM-HIGH Investigators. Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med 2014;371:288-290. doi: 10.1056/NEJMc1311039

97. Thompson G, Parhofer K. Current Role of Lipoprotein Apheresis. Current Atherosclerosis Reports 2019;21(7):26. doi: 10.1007/s11883-019-0787-5

98. Jaeger B, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009;6:229-239. doi: 10.1038/ncpcardio1456

99. Viney N, van Capelleveen J, Geary R et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016;388:2239-2253. doi: 10.1016/S0140-6736(16)31009-1

100. Schettler V, Neumann C, Peter C et al. The German lipoprotein apheresis registry (GLAR) - almost 5 years on. Clin Res Cardiol Suppl 2017;12(1):44-49. doi: 10.1007/s11789-017-0089-9

101. Beavers K, Beavers D, Bowden R et al. Effect of over-the-counter fish-oil administration on plasma Lp(a) levels in an end-stage renal disease population. J Ren Nutr 2009;19(6):443-449. doi: 10.1053/j.jrn.2009.06.005

102. Shakeri A, Tabibi H, Hedayati M. Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp(a) hyperlipoproteinemia. Hemodial Int 2010;14(4):498-504. doi: 10.1111/j.1542-4758.2010.00476.x

103. Kooshki A, Taleban F, Tabibi H et al. Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients. Ren Fail 2011;33(9):892-898. doi: 10.3109/0886022X.2011.605536

104. Bosch T, Thiery J, Gurland H et al. Long-term efficiency, biocompatibility, and clinical safety of combined simultaneous LDL-apheresis and haemodialysis in patients with hypercholes-terolaemia and end-stage renal failure. Nephrol Dial Transplant 1993;8(12):1350-1358